MARKET

XENE

XENE

Xenon Pharmaceut
NASDAQ
45.06
+0.45
+1.01%
Opening 12:29 12/05 EST
OPEN
44.99
PREV CLOSE
44.61
HIGH
45.27
LOW
44.66
VOLUME
132.55K
TURNOVER
--
52 WEEK HIGH
45.27
52 WEEK LOW
26.74
MARKET CAP
3.48B
P/E (TTM)
-11.5997
1D
5D
1M
3M
1Y
5Y
1D
Xenon Pharmaceuticals Unveils Promising Long-Term Epilepsy Treatment Data
TipRanks · 2h ago
Xenon announces new data on 48-month azetukalner OLE study data
TipRanks · 3h ago
Xenon Presents 48-Month Azetukalner OLE Study Data In Epilepsy At American Epilepsy Society Annual Meeting
Benzinga · 3h ago
Xenon Pharmaceuticals Reports 48-Month Azetukalner Study Shows 90.9% Seizure Reduction in Epilepsy Patients
Reuters · 3h ago
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
Barchart · 9h ago
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees
TipRanks · 18h ago
Xenon Pharmaceuticals Grants Equity Inducements to New Employees
Reuters · 19h ago
XENON PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 19h ago
More
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

Webull offers Xenon Pharmaceuticals Inc stock information, including NASDAQ: XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.